Trades, page-11

Oh ye- of little faith.
"Following the successful completion of major milestones across four drug development programs during 2015 to date, the Board has accelerated a strategic review of the business and its opportunities, and has appointed Ferghana Partners Group (New York, London, Boston) to progress various potential opportunities under review. Ferghana’s expertise is in acquisitions, divestitures, corporate partnering and financial transactions in the global healthcare sector."

According to various online articles the US Biotech sector is currently full steam ahead with aquisitions and mergers not seen since the GFC.Even unproven technologies are being snaped up.

"www.forbes.com/.../arleneweintraub/.../biotech-investing-hits-an-all-time"

Mesoblast utilized Ferghana's expertise to form a partnership with Celgene to the tune of $45 million.Mesoblast is now seeking a dual listing on the Nasdaq to raise $70 million,a feat not possible in the Australian Biotech industry.
I stand by a comment I made recently on HC that most "investors" in this sector cannot see the Forest for the Trees.